Pharmaceutical contracts
Fix the commercial terms that break once the product reaches the market.
Distribution, supply and licensing arrangements fail in South Africa when the commercial terms do not match the regulatory obligations carried by the licence holder, marketing-authorisation holder and distributor. The firm aligns the two before the contract is signed.
Who this is for
Pharmaceutical, biotechnology, medical-device and health-product companies
Typically instructed by: Regional and country legal counsel · legal business partners · market access · commercial
Scope
What can be instructed
- Distribution and supply
- Distribution, supply, agency and wholesale arrangements, including territory, exclusivity, forecasting and termination.
- Licensing
- In-licensing and out-licensing, field and territory definition, sublicensing and royalty mechanics.
- Quality and pharmacovigilance
- Quality agreements and pharmacovigilance agreements, and their alignment with the underlying commercial contract.
- Product liability and recalls
- Liability allocation, recall responsibility and cost-bearing, and the interaction with insurance.
- Local representation structures
- The South African contracting entity, the party holding the marketing authorisation, and the documented allocation of regulatory responsibility.
- Commercial effect of regulatory requirements
- How registration, licensing and labelling requirements bear on pricing, supply commitments and launch sequencing in the contract.
Before you instruct
What helps the firm assess the matter
- The counterparties and any related entities, for the conflicts check.
- The product or portfolio, and its South African registration status if relevant.
- Whether a global template governs, and which terms are negotiable.
- The commercial deadline the arrangement is working to.
jw van zyl inc